Segment, Geographic and Other Revenue Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Apr. 01, 2012		Apr. 03, 2011
Segment Reporting Information [Line Items]
Revenues	$ 15,405		$ 16,502
R&D Expenses	2,072	[1]	2,091	[1]
Earnings	2,553	[2]	3,118	[2]
Primary Care [Member]
Segment Reporting Information [Line Items]
Revenues	4,097		5,441
R&D Expenses	241		323
Earnings	2,670	[2]	3,551	[2]
Specialty Care And Oncology [Member]
Segment Reporting Information [Line Items]
Revenues	3,868		4,238
R&D Expenses	373		347
Earnings	2,596	[2]	2,878	[2]
Established Products and Emerging Markets [Member]
Segment Reporting Information [Line Items]
Revenues	5,100	[3]	4,545	[3]
R&D Expenses	73	[3]	56	[3]
Earnings	3,177	[2],[3]	2,481	[2],[3]
Animal Health and Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues	1,761		1,727
R&D Expenses	93		101
Earnings	495	[2]	489	[2]
Reportable Segments [Member]
Segment Reporting Information [Line Items]
Revenues	14,826		15,951
R&D Expenses	780		827
Earnings	8,938	[2]	9,399	[2]
Nutrition and other business activities [Member]
Segment Reporting Information [Line Items]
Revenues	579	[4]	551	[4]
R&D Expenses	682	[4]	857	[4]
Earnings	(539)	[2],[4]	(722)	[2],[4]
Corporate [Member]
Segment Reporting Information [Line Items]
R&D Expenses	286	[5]	325	[5]
Earnings	(1,820)	[2],[5]	(1,844)	[2],[5]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
R&D Expenses	10	[6]
Earnings	(1,458)	[2],[6]	(1,785)	[2],[6]
Acquisition-related costs [Member]
Segment Reporting Information [Line Items]
R&D Expenses	5	[7]	4	[7]
Earnings	(182)	[2],[7]	(575)	[2],[7]
Certain significant items [Member]
Segment Reporting Information [Line Items]
R&D Expenses	302	[8]	70	[8]
Earnings	(2,069)	[2],[8]	(1,208)	[2],[8]
Other unallocated [Member]
Segment Reporting Information [Line Items]
R&D Expenses	7	[9]	8	[9]
Earnings	$ (317)	[2],[9]	$ (147)	[2],[9]

[1] Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

[2] Income from continuing operations before provision for taxes on income.

[3] Revenues from the Established Products and Emerging Markets segment increased in the three months ended April 1, 2012 as compared to the three months ended April 3, 2011 due to additional products losing exclusivity and moving to the Established Products unit. Earnings from the Established Products and Emerging Markets segment increased in the three months ended April 1, 2012 as compared to the three months ended April 3, 2011 primarily due to additional products losing exclusivity and moving to the Established Products unit, as well as change in the mix of products.

[4] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[5] Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities and for Earnings includes, among other things, administration expenses, interest income/(expense), certain compensation and other costs not charged to our operating segments.

[6] Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

[7] Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information).

[8] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments. For Earnings in the first quarter of 2012, certain significant items for earnings includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $817 million, (ii) charges for certain legal matters of $775 million, (iii) certain asset impairment charges of $412 million and (iv) other charges of $65 million (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions--Net for additional information). For Earnings in the first quarter of 2011, certain significant items for earnings includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $572 million, (ii) charges for certain legal matters of $472 million, (iii) certain asset impairment charges of $157 million and (iv) other charges of $7 million (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions--Net for additional information). R&D Expenses For the first quarter of 2012 and 2011, certain significant items for R&D primarily reflect additional depreciation.

[9] Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.